Menopausal Disorders (MD) Competitive Landscape Report 2023: Bayer Emerges as the Top Sponsor, Backing 15 Trials, Followed by Astellas Pharma with 13 Trials

Dublin, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The "Menopausal Disorders (MD) - Competitive Landscape" report has been added to's offering.

The report offers a data-driven insight into the competitive landscape of MD therapeutics, shedding light on both the current scenario and future prospects.

With an anticipated 208 million total prevalent cases of MD in 2023 across 16 countries as per the epidemiology forecast, this segment of the pharmaceutical industry is poised for significant growth. Currently, estrogen receptor agonists dominate the landscape of marketed drugs for MD.

However, the pipeline for MD boasts 28 molecules, including two in pre-registration and four in Phase III, hinting at a wave of innovation on the horizon. Commercial sponsors have played a leading role in the clinical trials space for MD over the past decade, with Bayer emerging as the top sponsor, backing 15 trials, followed by Astellas Pharma with 13 trials.

In the realm of deals involving MD assets, partnerships have been a prevalent deal type in North America, while asset transactions have dominated in Europe, signifying robust activity and collaboration in this therapeutic area.


  • Disease Landscape
  • Disease Overview
  • Epidemiology Overview
  • Treatment Overview
  • Marketed Products Assessment
  • Breakdown by Mechanism of Action, Route of Administration
  • Product Profiles with Sales Forecast
  • Pricing and Reimbursement Assessment
  • Annual Therapy Cost
  • Time to Pricing and Time to Reimbursement
  • Pipeline Assessment
  • Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
  • Product Profiles with Sales Forecast
  • Late-to-mid-stage Pipeline Drugs
  • Phase Transition Success Rate and Likelihood of Approval
  • Clinical Trials Assessment
  • Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
  • Enrolment Analytics, Site Analytics, Feasibility Analysis
  • Deals Landscape
  • Mergers, Acquisitions, and Strategic Alliances by Region
  • Overview of Recent Deals
  • Commercial Assessment
  • Key Market Players
  • Future Market Catalysts

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the MD market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global MD market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Key Topics Covered:

1 Preface
1.1 Contents
1.2 Report Scope
1.3 List of Tables and Figures
1.4 Abbreviations

2 Key Findings

3 Disease Landscape
3.1 Disease Overview
3.2 Epidemiology Overview
3.3 Treatment Overview

4 Marketed Drugs Assessment
4.1 Leading Marketed Drugs
4.2 Overview by Mechanism of Action
4.3 Overview by Route of Administration
4.4 Marketed Drugs Profiles and Sales Forecasts

5 Pricing and Reimbursement Assessment
5.1 Annual Therapy Cost
5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment
6.1 Phase III Pipeline Drugs
6.2 Overview by Development Stage
6.3 Overview by Molecule Type
6.4 Overview by Mechanism of Action
6.5 Overview by Route of Administration
6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
6.7 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment
7.1 Historical Overview
7.2 Overview by Phase
7.3 Overview by Status
7.4 Overview by Phase for Ongoing and Planned Trials
7.5 Trials with Virtual Components
7.6 Geographic Overview
7.7 Single-Country and Multinational Trials by Region
7.8 Top 20 Sponsors with Breakdown by Phase
7.9 Top 20 Sponsors with Breakdown by Status
7.10 Overview by Endpoint Status
7.11 Overview by Race and Ethnicity
7.12 Enrollment Data
7.13 Top 20 countries for Trial Sites
7.14 Top 20 Sites Globally
7.15 Feasibility Analysis - Geographic Overview
7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape
8.1 Mergers, Acquisitions, and Strategic Alliances by Region
8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment
9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Contact Data